For both vectorization methods, we then selected 150 most similar parent-progeny pairs and analyzed them further to exclude the most unlikely entries, such as metabolites that are not used as drugs (but are present in the ZINC's World Drugs collection), dietary supplements, contrast agents, and drugs whose properties make them extremely unlikely candidates for COVID-19 treatment (e.g., bone resorption drugs, topical agents, or drug transport media). After merging the results from Mol2Vec